Clinical Trial Update: Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 neoadjuvant trial evaluating tislelizumab in combination with palbociclib for platinum-refractory bladder urothelial carcinoma is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Palbociclib (palbociclib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING